echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene's TYK2 inhibitor enters the clinic and expands its layout in the field of inflammation and immunology

    BeiGene's TYK2 inhibitor enters the clinic and expands its layout in the field of inflammation and immunology

    • Last Update: 2022-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 22, 2021, BeiGene announced that the first patient in a phase 1 clinical trial of the potent tyrosine kinase 2 (TYK2) inhibitor BGB-23339 under investigation has been administered
    .
    As a highly selective allosteric TYK2 inhibitor, BGB-23339 has shown effective inhibition of pro-inflammatory cytokines in preclinical studies, and is expected to be used in the treatment of diseases such as psoriasis and inflammatory bowel disease

    .
    The press release stated that this is BeiGene's first internally developed candidate therapy for inflammation and immune diseases

    .

    TYK2 is a member of the Janus kinase (JAK) family of proteins.
    It is an intracellular signal kinase that mediates interleukin (IL)-23, IL-12 and type I interferon signal transduction

    .
    It plays an important role in transmitting inflammation and immune response signals, and is considered to be related to the pathology of a variety of immune-mediated diseases

    .

    BGB-23339 is a highly selective allosteric TYK2 inhibitor
    .
    It is designed to target the regulatory pseudokinase (JH2) domain on TYK2.
    It has shown strong selectivity in preclinical studies and can effectively inhibit pro-inflammatory cytokines such as IL-12, IL-23 and type I IFN.

    .
    Its phase 1 clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and preliminary activity of BGB-23339, and it is expected that 115 healthy volunteers will be enrolled

    .

    Reference materials:

    [1] BeiGene Initiates First-in-Human Phase1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339.
    Retrieved November 22, 2021, from https:// original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.